Login to Your Account

The Wait is Over

New Venture Funds Target Canadian Innovation

By Peter Winter

Monday, June 11, 2012

It is often said that start-up and emerging biotechnology companies require patient capital in order to execute on their business plans. Unfortunately, for Canadian biotechs they have had to be extremely patient waiting for capital.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription